marginal zone lymphoma

News

BMS's Breyanzi is first CAR-T for marginal zone lymphoma

Bristol Myers Squibb has taken CAR-T therapy into new territory, after getting FDA approval for Breyanzi in marginal zone lymphoma.

News

Protego's $130m for amyloidosis drug, and other financings

Our latest crop of biotech financings has nine-figure rounds for Protego and Triana, with Excelsior Sciences and SciNeuro also raising new funds.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks